{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T04:06:01Z","timestamp":1774757161089,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,8,28]],"date-time":"2012-08-28T00:00:00Z","timestamp":1346112000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s00213-012-2850-6","type":"journal-article","created":{"date-parts":[[2012,8,27]],"date-time":"2012-08-27T04:18:30Z","timestamp":1346041110000},"page":"627-635","source":"Crossref","is-referenced-by-count":37,"title":["Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia"],"prefix":"10.1007","volume":"225","author":[{"given":"Jian-Jun","family":"Ou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoduo","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Feng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren-Rong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Ping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,8,28]]},"reference":[{"key":"2850_CR1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/YIC.0b013e32832c2624","volume":"24","author":"K Alptekin","year":"2009","unstructured":"Alptekin K, Hafez J, Brook S, Akkaya C, Tzebelikos E, Ucok A, El Tallawy H, Danaci AE, Lowe W, Karayal ON (2009) Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol 24:229\u2013238","journal-title":"Int Clin Psychopharmacol"},{"key":"2850_CR2","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","volume":"162","author":"A Breier","year":"2005","unstructured":"Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM (2005) Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 162:1879\u20131887","journal-title":"Am J Psychiatry"},{"key":"2850_CR3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00004850-200503000-00008","volume":"20","author":"RR Brown","year":"2005","unstructured":"Brown RR, Estoup MW (2005) Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. Int Clin Psychopharmacol 20:105\u2013112","journal-title":"Int Clin Psychopharmacol"},{"key":"2850_CR4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/JCP.0b013e3180ca83b1","volume":"27","author":"M Dossenbach","year":"2007","unstructured":"Dossenbach M, Treuer T, Kryzhanovskaya L, Saylan M, Dominguez S, Huang X (2007) Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa. J Clin Psychopharmacol 27:329\u2013337","journal-title":"J Clin Psychopharmacol"},{"key":"2850_CR5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1331\/JAPhA.2007.06090","volume":"47","author":"PM Garman","year":"2007","unstructured":"Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR (2007) Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia. J Am Pharm Assoc: JAPhA 47:373\u2013378","journal-title":"J Am Pharm Assoc: JAPhA"},{"key":"2850_CR6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","volume":"79","author":"DJ Gordon","year":"1989","unstructured":"Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8\u201315","journal-title":"Circulation"},{"key":"2850_CR7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/schbul\/sbp037","volume":"37","author":"KP Grootens","year":"2011","unstructured":"Grootens KP, van Veelen NM, Peuskens J, Sabbe BG, Thys E, Buitelaar JK, Verkes RJ, Kahn RS (2011) Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull 37:352\u2013361","journal-title":"Schizophr Bull"},{"issue":"Suppl 12","key":"2850_CR8","first-page":"18","volume":"68","author":"DC Henderson","year":"2007","unstructured":"Henderson DC (2007) Weight gain with atypical antipsychotics: evidence and insights. J clin psychiatry 68(Suppl 12):18\u201326","journal-title":"J clin psychiatry"},{"key":"2850_CR9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","volume":"3","author":"JE Hokanson","year":"1996","unstructured":"Hokanson JE, Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213\u2013219","journal-title":"J Cardiovasc Risk"},{"key":"2850_CR10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.7326\/0003-4819-150-7-200904070-00007","volume":"150","author":"S Ip","year":"2009","unstructured":"Ip S, Lichtenstein AH, Chung M, Lau J, Balk EM (2009) Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med 150:474\u2013484","journal-title":"Ann Intern Med"},{"key":"2850_CR11","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085\u20131097","journal-title":"Lancet"},{"key":"2850_CR12","doi-asserted-by":"crossref","unstructured":"Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S (2010) Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev: CD006654","DOI":"10.1002\/14651858.CD006654.pub2"},{"key":"2850_CR13","doi-asserted-by":"crossref","unstructured":"Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, Leucht S (2009) Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev: CD006627","DOI":"10.1002\/14651858.CD006627.pub2"},{"key":"2850_CR14","first-page":"305","volume":"48","author":"MR Law","year":"1994","unstructured":"Law MR, Wald NJ (1994) An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990. Eur J Clin Nutr 48:305\u2013325","journal-title":"Eur J Clin Nutr"},{"key":"2850_CR15","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1176\/appi.ajp.160.7.1209","volume":"160","author":"S Leucht","year":"2003","unstructured":"Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM (2003) Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160:1209\u20131222","journal-title":"Am J Psychiatry"},{"key":"2850_CR16","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209\u20131223","journal-title":"N Engl J Med"},{"key":"2850_CR17","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/15622970802269589","volume":"10","author":"H Lublin","year":"2009","unstructured":"Lublin H, Haug HJ, Koponen H, Sigmundsson T, Kolb SA (2009) Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. world j biol psychiatry: off j World Fed Soc Biol Psychiatry 10:710\u2013718","journal-title":"world j biol psychiatry: off j World Fed Soc Biol Psychiatry"},{"key":"2850_CR18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","volume":"80","author":"JP McEvoy","year":"2005","unstructured":"McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19\u201332","journal-title":"Schizophr Res"},{"key":"2850_CR19","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1176\/appi.ps.57.10.1482","volume":"57","author":"BJ Miller","year":"2006","unstructured":"Miller BJ, Paschall CB, Svendsen DP (2006) Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv 57:1482\u20131487","journal-title":"Psychiatr Serv"},{"key":"2850_CR20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","volume":"56","author":"S Mottillo","year":"2010","unstructured":"Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ (2010) The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 56:1113\u20131132","journal-title":"J Am Coll Cardiol"},{"key":"2850_CR21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.numecd.2010.07.003","volume":"20","author":"AG Olsson","year":"2010","unstructured":"Olsson AG (2010) HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin. Nutr Metab Cardiovasc Dis 20:553\u2013557","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2850_CR22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/schbul\/sbq042","volume":"38","author":"C Rummel-Kluge","year":"2012","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, Davis JM, Leucht S (2012) Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 38:167\u2013177","journal-title":"Schizophr Bull"},{"key":"2850_CR23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","volume":"123","author":"C Rummel-Kluge","year":"2010","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123:225\u2013233","journal-title":"Schizophr Res"},{"issue":"Suppl 21","key":"2850_CR24","first-page":"16","volume":"60","author":"GS Sachs","year":"1999","unstructured":"Sachs GS, Guille C (1999) Weight gain associated with use of psychotropic medications. J clin psychiatry 60(Suppl 21):16\u201319","journal-title":"J clin psychiatry"},{"key":"2850_CR25","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1176\/appi.ajp.161.10.1837","volume":"161","author":"GM Simpson","year":"2004","unstructured":"Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO (2004) Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 161:1837\u20131847","journal-title":"Am J Psychiatry"},{"key":"2850_CR26","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1176\/appi.ajp.162.8.1535","volume":"162","author":"GM Simpson","year":"2005","unstructured":"Simpson GM, Weiden P, Pigott T, Murray S, Siu CO, Romano SJ (2005) Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 162:1535\u20131538","journal-title":"Am J Psychiatry"},{"key":"2850_CR27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/appi.ajp.2010.08040484","volume":"168","author":"BL Strom","year":"2011","unstructured":"Strom BL, Eng SM, Faich G, Reynolds RF, D\u2019Agostino RB, Ruskin J, Kane JM (2011) Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry 168:193\u2013201","journal-title":"Am J Psychiatry"},{"key":"2850_CR28","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","volume":"374","author":"J Tiihonen","year":"2009","unstructured":"Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374:620\u2013627","journal-title":"Lancet"},{"key":"2850_CR29","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","volume":"27","author":"TM Wallace","year":"2004","unstructured":"Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487\u20131495","journal-title":"Diabetes Care"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-012-2850-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-012-2850-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-012-2850-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T00:24:30Z","timestamp":1562113470000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-012-2850-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,28]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["2850"],"URL":"https:\/\/doi.org\/10.1007\/s00213-012-2850-6","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,28]]}}}